DK2668183T3 - Hæmning af IL17 og IFN-gamma til behandling af autoimmun inflammation - Google Patents
Hæmning af IL17 og IFN-gamma til behandling af autoimmun inflammationInfo
- Publication number
- DK2668183T3 DK2668183T3 DK12703014.6T DK12703014T DK2668183T3 DK 2668183 T3 DK2668183 T3 DK 2668183T3 DK 12703014 T DK12703014 T DK 12703014T DK 2668183 T3 DK2668183 T3 DK 2668183T3
- Authority
- DK
- Denmark
- Prior art keywords
- ifn
- gamma
- inhibition
- treat autoimmune
- autoimmune inflammation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161437080P | 2011-01-28 | 2011-01-28 | |
| EP11152512 | 2011-01-28 | ||
| PCT/EP2012/051360 WO2012101263A1 (en) | 2011-01-28 | 2012-01-27 | Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2668183T3 true DK2668183T3 (da) | 2018-01-29 |
Family
ID=46577836
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12703014.6T DK2668183T3 (da) | 2011-01-28 | 2012-01-27 | Hæmning af IL17 og IFN-gamma til behandling af autoimmun inflammation |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US8354436B2 (da) |
| EP (1) | EP2668183B1 (da) |
| JP (1) | JP5883034B2 (da) |
| KR (1) | KR101865437B1 (da) |
| CN (1) | CN103459385B (da) |
| AR (1) | AR085038A1 (da) |
| AU (1) | AU2012210491B2 (da) |
| BR (1) | BR112013019256B1 (da) |
| CA (1) | CA2825779C (da) |
| DK (1) | DK2668183T3 (da) |
| EA (1) | EA026361B1 (da) |
| ES (1) | ES2664219T3 (da) |
| HU (1) | HUE036027T2 (da) |
| IL (1) | IL227682A0 (da) |
| MX (1) | MX348726B (da) |
| MY (1) | MY183974A (da) |
| PL (1) | PL2668183T3 (da) |
| PT (1) | PT2668183T (da) |
| RU (1) | RU2013139662A (da) |
| SG (1) | SG192198A1 (da) |
| TW (1) | TWI533867B (da) |
| UA (1) | UA110048C2 (da) |
| UY (1) | UY33885A (da) |
| WO (1) | WO2012101263A1 (da) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2668182T3 (pl) * | 2011-01-28 | 2018-11-30 | Immunic Ag | Inhibitowanie IL17 i IFN-gamma do leczenia zapalenia autoimmunologicznego |
| EP2738170B1 (en) * | 2011-07-29 | 2017-08-30 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| EP2809660B1 (en) | 2012-02-02 | 2016-01-20 | Ensemble Therapeutics Corporation | Macrocyclic compounds for modulating il-17 |
| UA117913C2 (uk) | 2012-05-31 | 2018-10-25 | Фінекс Фармас'Ютікалс Аг | КАРБОКСАМІД- АБО СУЛЬФОНАМІДЗАМІЩЕНІ ТІАЗОЛИ ТА СПОРІДНЕНІ ПОХІДНІ ЯК МОДУЛЯТОРИ ОРФАНОВОГО ЯДЕРНОГО РЕЦЕПТОРА RORγ |
| JO3215B1 (ar) | 2012-08-09 | 2018-03-08 | Phenex Pharmaceuticals Ag | حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy |
| US9707154B2 (en) | 2013-04-24 | 2017-07-18 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| WO2017221174A1 (en) * | 2016-06-22 | 2017-12-28 | Novartis Ag | Methods of treating vitiligo using interleukin-17 (il-17) antibodies |
| CA3043640A1 (en) * | 2016-11-11 | 2018-05-17 | Whitehead Institute For Biomedical Research | Human plasma-like medium |
| CN111433202A (zh) | 2017-09-06 | 2020-07-17 | 埃慕尼克股份公司 | 作为IL-17和IFN-γ抑制剂用于治疗自体免疫疾病和慢性炎症的1-(4-(异*唑-5-基)-1H-吡唑-1-基)-2-甲基丙-2-醇衍生物和相关化合物 |
| JPWO2019163945A1 (ja) * | 2018-02-22 | 2021-02-18 | 学校法人東海大学 | Ｉｌ−１７ａ活性阻害剤およびその用途 |
| RU2704967C1 (ru) * | 2018-06-19 | 2019-11-01 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Ярославский государственный педагогический университет им. К.Д. Ушинского (ЯГПУ им. К.Д. Ушинского) | Карбоксамидные производные изоксазолина, способ их получения и применения для лечения воспалительных заболеваний |
| WO2021027721A1 (zh) * | 2019-08-09 | 2021-02-18 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| CN112341439B (zh) * | 2019-08-09 | 2022-02-15 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| WO2021027729A1 (zh) * | 2019-08-09 | 2021-02-18 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| WO2023281097A1 (en) | 2021-07-09 | 2023-01-12 | Immunic Ag | Methods for treating cancer |
| WO2023198873A1 (en) | 2022-04-14 | 2023-10-19 | Immunic Ag | Deuterated rorgamma/rorgammat inverse agonists |
| WO2023232870A1 (en) | 2022-05-31 | 2023-12-07 | Immunic Ag | Rorg/rorgt modulators for the treatment of virus infections like covid-19 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6514977B1 (en) * | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
| RS50796B (sr) * | 2004-03-09 | 2010-08-31 | Boehringer Ingelheim Pharmaceuticals Inc. | 3-[4-heterociklil-1,2,3-triazol-1-il]-n-aril-benzamidi kao inhibitori produkcije citokina za lečenje hroničnih inflamatornih oboljenja |
| EP1968972B1 (en) * | 2005-12-23 | 2012-11-28 | F. Hoffmann-La Roche AG | Aryl-isoxazolo-4-yl-oxadiazole derivatives |
| CN102361867A (zh) * | 2009-01-23 | 2012-02-22 | 百时美施贵宝公司 | 在治疗自身免疫疾病和炎性疾病中作为s1p激动剂的取代的噁二唑衍生物 |
| PL2668182T3 (pl) * | 2011-01-28 | 2018-11-30 | Immunic Ag | Inhibitowanie IL17 i IFN-gamma do leczenia zapalenia autoimmunologicznego |
-
2012
- 2012-01-27 RU RU2013139662/04A patent/RU2013139662A/ru not_active Application Discontinuation
- 2012-01-27 HU HUE12703014A patent/HUE036027T2/hu unknown
- 2012-01-27 EA EA201300863A patent/EA026361B1/ru not_active IP Right Cessation
- 2012-01-27 AU AU2012210491A patent/AU2012210491B2/en active Active
- 2012-01-27 ES ES12703014.6T patent/ES2664219T3/es active Active
- 2012-01-27 CA CA2825779A patent/CA2825779C/en active Active
- 2012-01-27 WO PCT/EP2012/051360 patent/WO2012101263A1/en active Application Filing
- 2012-01-27 JP JP2013550894A patent/JP5883034B2/ja active Active
- 2012-01-27 KR KR1020137022373A patent/KR101865437B1/ko active IP Right Grant
- 2012-01-27 US US13/360,063 patent/US8354436B2/en active Active
- 2012-01-27 UA UAA201310355A patent/UA110048C2/ru unknown
- 2012-01-27 PL PL12703014T patent/PL2668183T3/pl unknown
- 2012-01-27 MX MX2013008722A patent/MX348726B/es active IP Right Grant
- 2012-01-27 BR BR112013019256-9A patent/BR112013019256B1/pt active IP Right Grant
- 2012-01-27 SG SG2013057583A patent/SG192198A1/en unknown
- 2012-01-27 CN CN201280010976.6A patent/CN103459385B/zh active Active
- 2012-01-27 PT PT127030146T patent/PT2668183T/pt unknown
- 2012-01-27 DK DK12703014.6T patent/DK2668183T3/da active
- 2012-01-27 MY MYPI2013002824A patent/MY183974A/en unknown
- 2012-01-27 EP EP12703014.6A patent/EP2668183B1/en active Active
- 2012-01-30 UY UY0001033885A patent/UY33885A/es not_active Application Discontinuation
- 2012-01-30 TW TW101102963A patent/TWI533867B/zh active
- 2012-01-30 AR ARP120100295A patent/AR085038A1/es active IP Right Grant
-
2013
- 2013-07-28 IL IL227682A patent/IL227682A0/en active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2668182T3 (da) | Hæmning af IL17 og IFN-gamma til behandling af autoimmun inflammation | |
| DK2668183T3 (da) | Hæmning af IL17 og IFN-gamma til behandling af autoimmun inflammation | |
| PH12016500024A1 (en) | Bromodomain inhibitor | |
| WO2014179564A8 (en) | Thiazolopyrrolidine inhibitors of ror-gamma | |
| EA201300730A1 (ru) | Производные индазолилтриазола | |
| WO2014028600A3 (en) | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | |
| EA201590534A1 (ru) | Новые бициклические производные | |
| WO2011153157A3 (en) | Benzoquinolone inhibitors of vmat2 | |
| AU2012214029A8 (en) | Rorgammat inhibitors | |
| MY181898A (en) | Heterocyclic compounds and uses thereof | |
| IN2014MN02652A (da) | ||
| IN2014MN02658A (da) | ||
| IN2014MN02657A (da) | ||
| DK3520805T3 (da) | Sammensætninger til behandling af myelofibrose | |
| EA201490567A1 (ru) | Новые бициклические производные дигидрохинолин-2-она | |
| WO2014153235A3 (en) | Arginine methyltransferase inhibitors and uses thereof | |
| WO2014153100A3 (en) | Arginine methyltransferase inhibitors and uses thereof | |
| WO2011113060A3 (en) | Antiviral compounds and methods of use thereof | |
| MX2017007607A (es) | Inhibidores de necrosis celular y metodos relacionados. | |
| AU2012213775A8 (en) | 7-azaindole derivatives | |
| EA201591360A1 (ru) | Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств | |
| EA201490471A1 (ru) | Пиридазиноновые соединения и их применение в качестве ингибиторов daao | |
| EA201792021A1 (ru) | Ингибитор jak | |
| EA201500628A1 (ru) | Индолкарбоксамидные производные в качестве антагонистов p2xрецепторов | |
| EA201500931A1 (ru) | Производные пиридин-4-ила |